Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

DNA-targeted drugs
Meza–Junco, Judith, Sawyer, Michael B.

Advances in Personalized Therapy for Lung Cancer | March 26, 2013 | Volume: No volume available | Issue: No issue available | Pages: 52-65

10.2217/ebo.11.251 Get It

Emerging drugs affecting the renin–angiotensin system
Danser, AH Jan, Roks, Anton J.M.

Clinical Applications of Renin–Angiotensin System Inhibitors | March 26, 2013 | Volume: No volume available | Issue: No issue available | Pages: 104-114

10.2217/ebo.11.183 Get It

Current treatment options in psoriasis: topical agents
Zitelli, Kristine B., Alikhan, Ali

Current and Emerging Treatments for Psoriasis | March 26, 2013 | Volume: No volume available | Issue: No issue available | Pages: 32-59

10.2217/ebo.11.27 Get It

Triptans for migraine
Diener, Hans‐Christoph , Dodick, David W.

Triptans for Migraine | March 26, 2013 | Volume: No volume available | Issue: No issue available | Pages: 2-4

10.2217/ebo.12.5 Get It

Pathophysiology of migraine & triptan mechanism of action
Halker, Rashmi, Vargas, Bert B.

Triptans for Migraine | March 26, 2013 | Volume: No volume available | Issue: No issue available | Pages: 6-15

10.2217/ebo.11.391 Get It

Meckel syndrome
Leightner, Amanda C., Harris, Peter C.

Polycystic Kidney Disease: from Bench to Bedside | March 26, 2013 | Volume: No volume available | Issue: No issue available | Pages: 76-89

10.2217/ebo.12.263 Get It

Pain and pain management in polycystic kidney disease
Czarnecki, Peter G. , Steinman, Theodore I.

Polycystic Kidney Disease: from Bench to Bedside | March 26, 2013 | Volume: No volume available | Issue: No issue available | Pages: 114-128

10.2217/ebo.12.137 Get It

Other new targeted therapies
Garcia, Jairo A., Roberts, Lewis R. , Roberts, Lewis R

Targeted Therapies for Hepatocellular Carcinoma | March 26, 2013 | Volume: No volume available | Issue: No issue available | Pages: 84-96

10.2217/ebo.11.267 Get It

Association of plasma and cortical amyloid beta is modulated by APOE ε4 status
Swaminathan, Shanker , Yoder, Karmen K. , West, John D. , Shen, Li , Kim, Sungeun , Inlow, Mark , Jagust, William, Mathis, Chester A. , Shaw, Leslie M. , Trojanowski, John Q. , Soares, Holly , Aisen, Paul, Petersen, Ronald C. , Weiner, Michael W. , Saykin, Andrew J. , Initiative, Alzheimer's Disease Neuroimaging, Risacher, Shannon L. , Foroud, Tatiana , Koeppe, Robert A. , Initiative, Alzheimer's Disease Neuroimaging, Saykin, Andrew J , Shen, Li

Alzheimer's & Dementia | March 26, 2013 | Volume: 10 | Issue: 1 | Pages: No page available

10.1016/j.jalz.2013.01.007 | PMID 23541187 Get It

AbstractBackgroundApolipoprotein E (APOE) ε4 allele's role as a modulator of the relationship between soluble plasma amyloid beta (Aβ) and fibrillar brain Aβ measured by Pittsburgh compound B positron emission tomography ([11C]PiB PET) has not been assessed.MethodsNinety‐six Alzheimer's Disease Neuroimaging Initiative participants with [11C]PiB scans and plasma Aβ1–40 and Aβ1–42 measurements at the time of PET scanning were included. Regional and voxelwise analyses of [11C]PiB data were used to determine the influence of APOE ε4 allele on association of plasma Aβ1–40, Aβ1–42, and Aβ1–40/Aβ1–42 with [11C]PiB uptake.ResultsIn APOE ε4− but not ε4+ participants, positive relationships between plasma Aβ1–40/Aβ1–42 and [11C]PiB uptake were observed. Modeling the interaction of APOE and plasma Aβ1–40/Aβ1–42 improved the explained variance in [11C]PiB binding compared with using APOE and plasma Aβ1–40/Aβ1–42 as separate terms.ConclusionsThe results suggest that plasma Aβ is a potential Alzheimer's disease biomarker and highlight the importance of genetic variation in interpretation of plasma Aβ levels.
The neuropsychology of normal aging and preclinical Alzheimer's disease
Caselli, Richard J. , Locke, Dona E.C. , Dueck, Amylou C. , Woodruff, Bryan K. , Hoffman‐Snyder, Charlene , Rademakers, Rosa , Fleisher, Adam , Reiman, Eric M. , Knopman, David S. , Dueck, A. C. , Locke, Dona E C

Alzheimer's & Dementia | March 26, 2013 | Volume: 10 | Issue: 1 | Pages: 84-92

10.1016/j.jalz.2013.01.004 | PMID 23541188 Get It

AbstractObjectiveA National Institute on Aging–sponsored work group on preclinical Alzheimer's disease (AD) articulated the need to characterize cognitive differences between normal aging and preclinical AD.MethodsSeventy‐one apolipoprotein E (APOE) ε4 homozygotes, 194 ε3/ε4 heterozygotes, and 356 ε4 noncarriers age 21 to 87 years who were cognitively healthy underwent neuropsychological testing every 2 years. Longitudinal trajectories of test scores were compared between APOE subgroups.ResultsThere was a significant effect of age on all cognitive domains in both APOE ε4 carriers and noncarriers. A significant effect of APOE ε4 gene dose was confined to the memory domain and the Dementia Rating Scale. Cross‐sectional comparisons did not discriminate the groups.ConclusionsAlthough cognitive aging patterns are similar in APOE ε4 carriers and noncarriers, preclinical AD is characterized by a significant ε4 gene dose effect that impacts memory and is detectable longitudinally. Preclinical neuropsychological testing strategies should emphasize memory‐sensitive measures and longitudinal design.